The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.
At the end of the course participants will be able to:
– have a deeper knowledge of diagnostic modalities for thoracic malignancies
– be familiar with the most up to date form of treatment according to stage
– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages
– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).
December 2, 2020
15:00
15:1515:15
15:30Introduction to the course
MODULE I – EARLY DISEASE
I° SESSION
CHAIR: Marco Scarci, Enrico Ruffini
15:30
15:40Nelson study: what have we learnt and what is left to do?
Tommy D’Amico
15:40
15:50Radiologic diagnosis of lung cancer: when is it enough?
Alexander Patterson
15:50
16:00New bronchoscopic techniques: friend or foe?
Kevin Lau
MODULE I – EARLY DISEASE
II° SESSION
CHAIR: Giuseppe Cardillo, Giulia Veronesi
16:00
16:10Resection vs surveillance for GGOs
Piergiorgio Solli
16:10
16:20Surgery vs SBRT for operable patients: is there a role?
Stefano Arcangeli
16:20
16:30Neoadjuvant treatments for early stage lung cancer: is there a role?
Kostas Papagiannopoulos
MODULE I – EARLY DISEASE
III° SESSION
CHAIR: Federico Raveglia, Lorenzo Rosso
16:30
16:40Where do we draw the line for indications for surgery? The truly inoperable patient
Alex Brunelli
16:40
16:50Ecmo for thoracic surgery
Pierre Emmanuel Falcoz
16:50
17:00How much can we push minimally invasive surgery?
Hasan Batirel
17:00
17:20KEY NOTE SESSION: Uniportal VATS complex anatomic segmentectomies
Diego Gonzalez Rivas
17:20
17:30Q&A
17:30
Closing the firs webinar module
December 3, 2020
15:00
15:15Start of the connection to the webinar
15:15
15:30Introduction to the course
MODULE II – ADVANCED DISEASE
I° SESSION
CHAIR: Diego Cortinovis
15:30
15:40Immunotherapy in resectable NSCLC
Matteo Giaj Levra
15:40
15:50News in immunotherapy world in advanced NSCLC: improving the bar
Nir Peled
15:50
16:00Neoadjuvant strategies in oncogene addicted tumors: is it now the time?
Ignacio Gil-Bazo
MODULE II – ADVANCED DISEASE
II° SESSION
CHAIR: Paolo Bidoli, Diego Cortinovis
16:00
16:10Oncogene addicted tumors: new OMA’s to know
Christian Rolfo
16:10
16:20SCLC a new dawn or the same old refrain
Diego Cortinovis
16:20
16:30Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront
Tommy D’Amico
MODULE II – ADVANCED DISEASE
III° SESSION
CHAIR: Diego Cortinovis, Christian Rolfo
16:30
16:40Treatment of (un)resactable stage III lung cancer
Federico Cappuzzo
16:40
16:50Oligometastatic disease: when is too much for surgery?
Gaetano Rocco
16:50
17:00Multimodality approach for orphan diseases: MPM and SCLC
Jordi Remon
17:00
17:30Q&A
17:30
Closing of the webinar
2/3 DECEMBER 2020 – MILANO
The multidisciplinary treatment of lung cancer